Medicine & Life Sciences
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
10%
Acute Myeloid Leukemia
100%
Allogeneic Cells
14%
asciminib
28%
Azacitidine
16%
B-Cell Chronic Lymphocytic Leukemia
11%
Blast Crisis
9%
blinatumomab
22%
Bone Marrow
8%
bosutinib
13%
Cladribine
10%
Clofarabine
9%
Cyclophosphamide
16%
Cytarabine
17%
Cytogenetics
15%
Dasatinib
27%
Decitabine
17%
Dexamethasone
14%
Doxorubicin
13%
Drug Therapy
26%
fludarabine
7%
Imatinib Mesylate
9%
INCB018424
8%
Induction Chemotherapy
7%
Inotuzumab Ozogamicin
33%
Leukemia
11%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
39%
Leukemia, Myeloid, Chronic Phase
48%
Leukemia, Myelomonocytic, Chronic
20%
Multivariate Analysis
7%
Mutation
34%
Myelodysplastic Syndromes
34%
Neoplasms
13%
PCI 32765
10%
Philadelphia Chromosome
50%
ponatinib
32%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
61%
Primary Myelofibrosis
13%
Progression-Free Survival
16%
Propensity Score
14%
Protein-Tyrosine Kinases
50%
Recurrence
12%
Residual Neoplasm
10%
Safety
9%
Stem Cell Transplantation
17%
Survival
51%
Survival Rate
12%
Therapeutics
24%
venetoclax
76%
Vincristine
18%